Development and internal validation of a CatBoost-SHAP-guided nomogram for significant liver fibrosis in children with chronic hepatitis B.
- 1Department of Infectious Diseases, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, China.
Abstract
Background
Significant liver fibrosis can develop in children with chronic hepatitis B (CHB), yet liver biopsy is invasive and unsuitable for repeated assessment. We developed an interpretable, non-invasive prediction model for significant fibrosis in pediatric CHB and evaluated whether baseline risk stratification was associated with subsequent treatment outcomes.Methods
This retrospective study included 232 children with CHB who underwent liver biopsy, with significant fibrosis defined as Scheuer stage S ≥ 2. Patients were randomly assigned to a development cohort (80%) and a held-out test set (20%). A CatBoost model with Bayesian hyperparameter optimization was used to identify the most informative predictors, and these variables were incorporated into a logistic regression nomogram guided by Shapley additive explanations (SHAP). Model performance was evaluated by discrimination, calibration, decision curve analysis, and DeLong testing. Associations between baseline risk groups and longitudinal outcomes were examined using generalized estimating equations adjusted for age and sex and Kaplan-Meier analyses.Results
Significant fibrosis was identified in 96 children (41.4%). Liver stiffness measurement, alanine aminotransferase, and platelet count were retained in the final model. The nomogram achieved an area under the receiver operating characteristic curve (AUC) of 0.828 (95% CI, 0.767-0.889) in the development cohort and 0.782 (95% CI, 0.637-0.927) in the held-out test cohort, with performance comparable to that of the CatBoost model (P = 0.240). Compared with the low-risk group, high-risk patients showed greater longitudinal reductions in alanine and aspartate aminotransferase, whereas longitudinal changes in liver stiffness measurement and hepatitis B virus DNA were similar between groups. Conversely, low-risk patients achieved virological suppression, HBeAg seroconversion, and biochemical response earlier than those classified as high risk.Conclusions
An interpretable three-variable prediction model based on CatBoost-guided feature selection accurately identified significant fibrosis in children with CHB while maintaining performance comparable to the machine-learning model. Baseline risk stratification was also associated with subsequent treatment outcomes, although external validation is needed before clinical implementation.
Related
- Development and internal validation of a nomogram-based screening tool for concurrent autoimmune hepatitis in children with intestinal diseases: a retrospective cohort study.
- Development and Internal Validation of a Preoperative Risk Stratification Model for Difficult Laparoscopic Cholecystectomy in Acute Cholecystitis
- Development and internal validation of a clinical risk score for early delirium detection in older emergency department patients
- Development and internal validation of a nomogram for predicting bacterial meningitis in preterm infants with late-onset sepsis
- Development and internal validation of machine learning models for predicting lymph node metastasis in cutaneous head and neck melanoma
BibTeX
@article{zhang2026development,
title = {{Development and internal validation of a CatBoost-SHAP-guided nomogram for significant liver fibrosis in children with chronic hepatitis B.}},
author = {Yuanzhen Zhang and Tingting Wu and Yunan Chang and Xiaorong Peng and Kai Zhu and Yijing Liu and Tingting Shang and Tao Qin and Jing Zhu and Jiao Tian and Ruiqiu Zhao and Hongmei Xu},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1927678},
url = {https://europepmc.org/article/MED/42898216},
note = {CC BY},
}
RIS
TY - JOUR
TI - Development and internal validation of a CatBoost-SHAP-guided nomogram for significant liver fibrosis in children with chronic hepatitis B.
AU - Yuanzhen Zhang
AU - Tingting Wu
AU - Yunan Chang
AU - Xiaorong Peng
AU - Kai Zhu
AU - Yijing Liu
AU - Tingting Shang
AU - Tao Qin
AU - Jing Zhu
AU - Jiao Tian
AU - Ruiqiu Zhao
AU - Hongmei Xu
PY - 2026
DA - 2026/10/05
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1927678
UR - https://europepmc.org/article/MED/42898216
AB - Background Significant liver fibrosis can develop in children with chronic hepatitis B (CHB), yet liver biopsy is invasive and unsuitable for repeated assessment. We developed an interpretable, non-invasive prediction model for significant fibrosis in pediatric CHB and evaluated whether baseline risk stratification was associated with subsequent treatment outcomes.Methods This retrospective study included 232 children with CHB who underwent liver biopsy, with significant fibrosis defined as Scheuer stage S ≥ 2. Patients were randomly assigned to a development cohort (80%) and a held-out test set (20%). A CatBoost model with Bayesian hyperparameter optimization was used to identify the most informative predictors, and these variables were incorporated into a logistic regression nomogram guided by Shapley additive explanations (SHAP). Model performance was evaluated by discrimination, calibration, decision curve analysis, and DeLong testing. Associations between baseline risk groups and longitudinal outcomes were examined using generalized estimating equations adjusted for age and sex and Kaplan-Meier analyses.Results Significant fibrosis was identified in 96 children (41.4%). Liver stiffness measurement, alanine aminotransferase, and platelet count were retained in the final model. The nomogram achieved an area under the receiver operating characteristic curve (AUC) of 0.828 (95% CI, 0.767-0.889) in the development cohort and 0.782 (95% CI, 0.637-0.927) in the held-out test cohort, with performance comparable to that of the CatBoost model (P = 0.240). Compared with the low-risk group, high-risk patients showed greater longitudinal reductions in alanine and aspartate aminotransferase, whereas longitudinal changes in liver stiffness measurement and hepatitis B virus DNA were similar between groups. Conversely, low-risk patients achieved virological suppression, HBeAg seroconversion, and biochemical response earlier than those classified as high risk.Conclusions An interpretable three-variable prediction model based on CatBoost-guided feature selection accurately identified significant fibrosis in children with CHB while maintaining performance comparable to the machine-learning model. Baseline risk stratification was also associated with subsequent treatment outcomes, although external validation is needed before clinical implementation.
SN - 2296-858X
ER -